SCHEMBL3125142

SCHEMBL3125142

O=C(Cl)Sc1ccccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 1/20 0.52
EHMT1 Q9H9B1 1/20 0.52
APOBEC3G Q9HC16 1/20 0.52
ALDH1A1 P00352 5/20 0.49
KMT2A Q03164 2/20 0.45
MAPT P10636 1/20 0.45
MEN1 O00255 1/20 0.45
PKM P14618 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
LMNA P02545 2/20 0.44
POLB P06746 2/20 0.44
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
RAB9A P51151 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
HPGD P15428 3/20 0.42
HSD17B10 Q99714 3/20 0.42
NPC1 O15118 3/20 0.42
KDM4E B2RXH2 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3075428 0.83 EHMT2 (0.56) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL5633792 0.83 EHMT2 (0.56) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL1479297 0.81 ALDH1A1 (0.55) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL3070731 0.79 EHMT2 (0.52) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL4757038 0.79 EHMT2 (0.52) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL4483430 0.76 ALDH1A1 (0.54) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
Bicarbonate SCHEMBL16975005 0.75 ALDH1A1 (0.53) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL31289372 0.75
SCHEMBL1607377 0.75 LMNA (0.51) EHMT2EHMT1APOBEC3GALDH1A1KMT2A
SCHEMBL14524405 0.75 EHMT2 (0.47) EHMT2EHMT1APOBEC3GALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12565468-B2 Processes and intermediates for the preparations of Carboprost and Carboprost Tromethamine, and Carboprost Tromethamine prepared therefrom CHIROGATE INTERNATIONAL INC. (TW) 2026-03-03 US disclosed
EP-4509492-A2 PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM Chirogate International Inc. (TW) 2025-02-19 EP disclosed
US-20230131316-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM CHIROGATE INTERNATIONAL INC. (TW) 2023-04-27 US disclosed
US-20230097470-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM CHIROGATE INTERNATIONAL INC. (TW) 2023-03-30 US disclosed
EP-4140982-A2 PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM Chirogate International Inc. (TW) 2023-03-01 EP disclosed
US-10822321-B2 Processes and intermediates for the preparations of isomer free prostaglandins CHIROGATE INTERNATIONAL INC. (TW) 2020-11-03 US disclosed
US-20180251442-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS CHIROGATE INTERNATIONAL INC. (TW) 2018-09-06 US disclosed
US-9994543-B2 Processes and intermediates for the preparations of isomer free prostaglandins CHIROGATE INTERNATIONAL INC. (TW) 2018-06-12 US disclosed
US-20180050999-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS CHIROGATE INTERNATIONAL INC. (TW) 2018-02-22 US disclosed
US-9890135-B1 Processes and intermediates for the preparations of isomer free prostaglandins CHIROGATE INTERNATIONAL INC. (TW) 2018-02-13 US disclosed
US-20040077021-A1 Derivatives, conjugates, and antibodies for detecting ecstasy-class analytes ROCHE DIAGNOSTICS CORPORATION 2004-04-22 US disclosed
US-20030175995-A1 Compounds, antibodies, reagent kits, methods of producing antibodies, and methods of detecting analytes ROCHE DIAGNOSTICS OPERATIONS, INC. 2003-09-18 US disclosed
US-20030170917-A1 Compounds, antibodies, reagent kits, methods of producing antibodies, and methods of detecting analytes ROCHE DIAGNOSTICS CORPORATION 2003-09-11 US disclosed
EP-1340981-A2 Antibodies for detecting amphetamine derivatives Roche Diagnostics GmbH (DE) 2003-09-03 EP disclosed
EP-1340980-A1 Derivatives of amphetamine, antibodies against said derivatives, reagent kits, methods of producing said antibodies, and methods of detecting said derivatives Roche Diagnostics GmbH (DE) 2003-09-03 EP disclosed
US-6306979-B1 Derivatized carbon monoxide copolymers BASF AKTIENGESELLSCHAFT (DE) 2001-10-23 US disclosed
US-5719139-A BACTERICIDES ZENECA LIMITED (GB) 1998-02-17 US disclosed
EP-0722945-A1 9-oxo-1-azabicyclo(5.2.0)non-2,3-diene-2-carboxylic acid derivatives as antibiotics ZENECA LIMITED (GB) 1996-07-24 EP disclosed
US-5490980-A TRANSGLUTAMINASE CROSSLINKS PROTEINS BY CATALYZING THE ACTIVE INGREDIANTS TO GLUTAMINE RESIDUES CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) 1996-02-13 US disclosed
US-4643991-A TREATMENT OF EMPHYSEMA THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 1987-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230097470-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM PTGES, PTGES2, PTGIS EHMT2 2607/4885EHMT1 2760/4885APOBEC3G 1403/4885
US-20180251442-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS PTGER2, PTGES2, PTGER1 EHMT2 4230/4885EHMT1 4747/4885APOBEC3G 3368/4885
US-20180050999-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS PTGER2, PTGES2, PTGER1 EHMT2 4230/4885EHMT1 4747/4885APOBEC3G 3368/4885
US-20230131316-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM PTGES, PTGES2, PTGIS EHMT2 2607/4885EHMT1 2760/4885APOBEC3G 1403/4885
US-10822321-B2 Processes and intermediates for the preparations of isomer free prostaglandins PTGER2, PTGES2, PTGER1 EHMT2 4230/4885EHMT1 4747/4885APOBEC3G 3368/4885
US-12565468-B2 Processes and intermediates for the preparations of Carboprost and Carboprost Tromethamine, and Carboprost Tromethamine prepared therefrom PGF, PTGIS, PTGS1 EHMT2 346/4885EHMT1 194/4885APOBEC3G 1483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.